Positing tumor metabolomic microenvironments to be sensitive to prostate cancer characteristics, we investigated the clinical potential of tissue magnetic resonance spectroscopy (MRS) analysis of human histologically-benign (Hb; no histologically identifiable prostate cancer cells or glands) samples that were obtained from cancerous prostates. The gene discussed is GSTM1; the disease is prostate cancer.